Endocrine Therapy Drugs (ETDs) Market Analysis & Forecast 2032

The human endocrine system is a messenger system that comprises a complex network of glands and organs. Hormones, also known as the chemical messengers of the body, released by the glands of the endocrine system into the circulatory system of the body, thus helping in regulation of distant target organs (stomach, liver, etc.) in the human body. Endocrine therapy or hormone therapy refers to addition, removal, or blocking of the action of hormones in order to treat diseases such as breast cancer, diabetes, etc., postmenopausal symptoms, and act as a method of contraception. Endocrine therapy mostly consists of an agent targeting either the hormone responsible for a particular disease or the organ producing that particular hormone. Aromatase inhibitors such as Letrozole, Anastrozole, and Exemestane decrease peripheral estrogen (sex hormone responsible for development and regulation of female reproductive system) synthesis through inhibition of aromatase, the enzyme essential for production of estrogen. Selective estrogen receptor modulators (SERMs; such as tamoxifen and toremifene) and selective estrogen receptor degraders (SERDs; such as fulvestrant) directly target the estrogen receptor.

The global endocrine therapy drugs (ETDs) market is estimated to be valued at US$ 28,958.4 million in 2022 and is expected to exhibit a CAGR of 5.1% over the forecast period (2022-2030).

Figure 1. Global Endocrine Therapy Drugs (ETDs) Market Share (%), By Region, 2022

To learn more about this report, Request sample copy

The increasing incidence of chronic diseases such as breast cancer, diabetes, and others is expected to drive the growth of the global endocrine therapy drugs (ETDs) market over the forecast period.

For instance, according to the data published by the American Cancer Society in January 2022, it is estimated that there are over 3.8 million women with a history of breast cancer in the U.S., as of January 2022. The same source also states that the incidence rates of breast cancer in the U.S. have increased by 0.5% per year.

Figure 2. Global Endocrine Therapy Drugs (ETDs) Market Value (US$ Mn), By Drug Type, 2022

To learn more about this report, Request sample copy

The increasing research and development activities for the development of novel endocrine therapy drugs (ETDs) for the treatment of diseases such as breast cancer, diabetes, and others is expected to drive the market growth over the forecast period.

For instance, in October 2021, Eli Lilly and Company, a U.S based pharmaceutical company initiated Phase 3, randomized clinical trials to evaluate the efficacy of its endocrine therapy drug imlunestrant, a selective estrogen receptor degrader (SERD), alone and in combination with abemaciclib, a kinase inhibitor drug for the treatment of breast cancer patients who are estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). These clinical trials are expected to be completed by September 2026.

Key players operating in the market are focusing on submitting applications for the approval of endocrine therapy drugs (ETDs), which is expected to drive growth of the global endocrine therapy drugs (ETDs) market over the forecast period.

For instance, in April 2021, Myovant Sciences GmbH, a U.K. based bio-pharmaceutical company and Pfizer Inc., a U.S. based pharmaceutical company announced that they have received the U.S. Food and Drug Administration (FDA) approval for their supplement new drug application for MYFEMBREE, an endocrine therapy drug for pain management associated with endometriosis.

Global Endocrine Therapy Drugs (ETDs) Market – Impact of Coronavirus (Covid-19) Pandemic

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 392 million population leading to more than 5.7 million deaths as of January 30, 2022. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. However, the COVID-19 pandemic is expected to show a positive impact on the overall growth of the endocrine therapy drugs (ETDs) market owing to the growing preference of physicians in adoption of endocrine therapy for safely delaying surgery in the treatment of breast cancer amidst the COVID-19 pandemic.

For instance, according to an article published by the Breast Cancer Research and Treatment journal in March 2021, a survey was carried out from May-June, 2020, amongst U.S. medical oncologists, radiation oncologists, and surgeons involved in clinical trials organizations. From the results of this survey it was found that before COVID-19 pandemic, around 46% respondents rarely used neoadjuvant endocrine therapy (NET) for deferral of surgery, whereas, during the pandemic most of the physicians preferred the use of NET and recommended omission of axillary lymph node dissection (ALND) surgery (removal of lymph nodes to stop breast cancer from spreading) after 1-3 months use of NET.

Global Endocrine Therapy Drugs (ETDs) Market - Restraint

The side effects associated with the use of endocrine therapy drugs (ETDs) is one of the major factor that is expected to hinder growth of the global endocrine therapy drugs (ETDs) market over the forecast period. For instance, according to data published by the National Cancer Institute (a part of NIH-National Institutes of Health) in July 2021, endocrine therapy drugs are associated with side effects such as hot flashes, night sweats, vaginal dryness, mood swings, depression, loss of libido, and others.

Key Players

Major players operating in the global endocrine therapy drugs (ETDs) market include Novo Nordisk A/S, AstraZeneca, Generex Biotechnology, Orion Pharma AB, Sanofi, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co.,Inc., Bayer AG, Eli Lilly and Company, Abbott, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., TherapeuticsMD, Inc., Pfizer Inc., Allergan, BioSante Pharmaceuticals, Amgen Inc., Noven Pharmaceuticals, Inc., and QuatRx Pharmaceuticals.